Cargando…
The Use of Aspirin to Reduce the Risk of Thrombotic Events in Patients With End-Stage Renal Disease: Protocol for a Randomized Controlled Trial
BACKGROUND: End-stage renal disease (ESRD) is the last stage of chronic kidney disease, mainly caused by type 2 diabetes mellitus and characterized by an increased mortality risk related to cardiovascular disease. Low-dose aspirin (acetylsalicylic acid or ASA) seems to effectively prevent cardiovasc...
Autores principales: | Lemos Cerqueira, Tiago, Fartolino Guerrero, Armando, Pérez Fermin, Clara Krystal, Wang, Ricardo, Balbino, Evelin Elfriede, Breeze, Janis L, Gonzalez Mego, Paola, Argentina Silva, Daniele, Omer, Walid Ezzeldin, Vandevelde, Nathalie Monique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JMIR Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107730/ https://www.ncbi.nlm.nih.gov/pubmed/30093367 http://dx.doi.org/10.2196/10516 |
Ejemplares similares
-
Thrombotic Events Associated to Aspirin Therapy
por: Doutremepuich, Christian, et al.
Publicado: (2012) -
Profiling the eicosanoid networks that underlie the anti- and pro-thrombotic effects of aspirin
por: Crescente, Marilena, et al.
Publicado: (2020) -
Preparation and Characterization of a Novel Aspirin Derivative with Anti-Thrombotic and Gastric Mucosal Protection Properties
por: Zhen, Xi-E, et al.
Publicado: (2014) -
SARS-COV-2 PLATELET FUNCTION & THROMBOTIC COMPLICATIONS: EFFECTS OF ASPIRIN THERAPY IN COVID-19
por: Bhandari, Rohan, et al.
Publicado: (2021) -
Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention
por: Ornelas, Argentina, et al.
Publicado: (2017)